Cowen and Company’s Cartesian Growth Corp II RENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-153,474
Closed -$1.76M 243
2024
Q3
$1.76M Sell
153,474
-319,909
-68% -$3.64M 0.06% 126
2024
Q2
$5.34M Buy
473,383
+35,211
+8% +$395K 0.15% 59
2024
Q1
$4.87M Buy
438,172
+212,546
+94% +$2.35M 0.19% 58
2023
Q4
$2.47M Sell
225,626
-336,900
-60% -$3.67M 0.16% 95
2023
Q3
$6.11M Buy
562,526
+542,845
+2,758% +$5.82M 0.43% 49
2023
Q2
$210K Buy
+19,681
New +$208K 0.02% 209
2023
Q1
Sell
-38,573
Closed -$395K 665
2022
Q4
$395K Buy
+38,573
New +$391K 0.04% 140

Other funds holding RENE

Cowen and Company's RENE Position: Q4 2024 in Review

Cowen and Company sold out of Cartesian Growth Corp II (RENE) in Q4 2024, closing a stake of 153,474 shares — an estimated $1.76M sold.

Cowen and Company first reported a position in RENE in Q4 2022 and held it in 7 quarters. The position peaked at $6.11M in Q3 2023. 19 funds tracked by Wall St. Rank hold RENE as of Q4 2024.

  • Cowen and Company reported no remaining Cartesian Growth Corp II position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 153,474 Cartesian Growth Corp II shares in Q4 2024, an estimated $1.76M.
  • Cowen and Company first reported a position in Cartesian Growth Corp II in Q4 2022 and held it in 7 quarters.
  • Cowen and Company's Cartesian Growth Corp II position peaked at $6.11M in Q3 2023.
  • 19 funds tracked by Wall St. Rank held Cartesian Growth Corp II as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.